secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2021-10-14T23:59:59+00:00
Accession:  0001654954-21-011095
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics President/CFO Michael Jebsen to depart Oct 29; CEO Giordano becomes President; interim CFO appointed
--------------------------------------------------------------------------------

- Michael B. Jebsen (President & CFO) to depart Oct 29, 2021; receives 12 months base salary severance + prorated bonus.
- CEO Christopher T. Giordano will assume additional role of President effective upon separation.
- Eliot M. Lurier appointed Interim CFO via Danforth Advisors; Danforth receives $400/hour for his services.
- Jebsen to provide advisory services through April 2022 at $275/hour under a 6-month consulting agreement.
- Board initiates search for a permanent Chief Financial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/0001654954-21-011095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495421011095/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-21-011095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer